NCT03209401: Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies

NCT03209401
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: BRCA+, DNA damage repair mutations
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Misc Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Patients must have DNA damage repair germline (inherited) or somatic mutations. See trial for all eligible mutations
Exclusions: Known or suspected CNS metastases- see trial for details
https://ClinicalTrials.gov/show/NCT03209401

Comments are closed.

Up ↑